| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 339 | 2024 | 970 | 31.460 |
Why?
|
| HIV-1 | 157 | 2022 | 438 | 12.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 98 | 2023 | 218 | 7.580 |
Why?
|
| Anti-HIV Agents | 77 | 2022 | 169 | 6.520 |
Why?
|
| Lymphocyte Activation | 84 | 2022 | 209 | 6.490 |
Why?
|
| CD8-Positive T-Lymphocytes | 67 | 2022 | 170 | 5.310 |
Why?
|
| Anti-Retroviral Agents | 25 | 2022 | 51 | 4.430 |
Why?
|
| Gastrointestinal Microbiome | 21 | 2023 | 180 | 4.410 |
Why?
|
| Antiretroviral Therapy, Highly Active | 60 | 2022 | 139 | 4.270 |
Why?
|
| Microbiota | 18 | 2022 | 105 | 4.210 |
Why?
|
| Monocytes | 43 | 2023 | 116 | 4.210 |
Why?
|
| Humans | 504 | 2024 | 29337 | 4.070 |
Why?
|
| Inflammation | 43 | 2023 | 344 | 3.780 |
Why?
|
| T-Lymphocytes | 50 | 2022 | 211 | 3.710 |
Why?
|
| Viral Load | 70 | 2022 | 197 | 3.700 |
Why?
|
| HIV | 39 | 2022 | 92 | 3.540 |
Why?
|
| Biomarkers | 64 | 2023 | 689 | 3.490 |
Why?
|
| Flow Cytometry | 69 | 2022 | 198 | 3.190 |
Why?
|
| B-Lymphocytes | 21 | 2018 | 81 | 3.160 |
Why?
|
| Adult | 217 | 2021 | 8601 | 3.140 |
Why?
|
| CD4 Lymphocyte Count | 78 | 2022 | 150 | 3.050 |
Why?
|
| Intestinal Mucosa | 15 | 2021 | 220 | 2.960 |
Why?
|
| Female | 252 | 2023 | 16197 | 2.930 |
Why?
|
| RNA, Viral | 59 | 2021 | 148 | 2.770 |
Why?
|
| Middle Aged | 177 | 2022 | 9823 | 2.710 |
Why?
|
| Killer Cells, Natural | 31 | 2023 | 91 | 2.680 |
Why?
|
| Cytokines | 39 | 2023 | 347 | 2.600 |
Why?
|
| T-Lymphocyte Subsets | 34 | 2022 | 86 | 2.450 |
Why?
|
| Acquired Immunodeficiency Syndrome | 36 | 2021 | 90 | 2.410 |
Why?
|
| Vagina | 20 | 2020 | 46 | 2.190 |
Why?
|
| Immunophenotyping | 44 | 2021 | 80 | 2.190 |
Why?
|
| Leukocytes, Mononuclear | 32 | 2023 | 96 | 2.170 |
Why?
|
| Atherosclerosis | 13 | 2023 | 72 | 2.170 |
Why?
|
| Immunity, Innate | 20 | 2021 | 90 | 2.150 |
Why?
|
| Carotid Artery Diseases | 14 | 2023 | 44 | 2.150 |
Why?
|
| Lymphocyte Subsets | 19 | 2012 | 30 | 2.110 |
Why?
|
| T-Lymphocytes, Regulatory | 17 | 2018 | 49 | 2.090 |
Why?
|
| Male | 174 | 2023 | 15621 | 2.010 |
Why?
|
| Aging | 25 | 2023 | 1593 | 1.930 |
Why?
|
| Cytomegalovirus Infections | 10 | 2020 | 79 | 1.910 |
Why?
|
| Virus Replication | 31 | 2018 | 92 | 1.910 |
Why?
|
| Antigens, CD | 36 | 2021 | 99 | 1.790 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 14 | 2023 | 22 | 1.780 |
Why?
|
| Antibodies, Viral | 23 | 2023 | 87 | 1.780 |
Why?
|
| Immunity, Mucosal | 8 | 2021 | 29 | 1.770 |
Why?
|
| Interleukin-6 | 15 | 2023 | 108 | 1.700 |
Why?
|
| HIV Seropositivity | 28 | 2015 | 94 | 1.650 |
Why?
|
| Lymphocytes | 29 | 2020 | 110 | 1.570 |
Why?
|
| Gene Expression Regulation | 13 | 2021 | 284 | 1.570 |
Why?
|
| Genitalia, Female | 13 | 2016 | 28 | 1.540 |
Why?
|
| Dysbiosis | 8 | 2020 | 64 | 1.410 |
Why?
|
| Dendritic Cells | 14 | 2015 | 56 | 1.390 |
Why?
|
| Cervix Uteri | 14 | 2015 | 38 | 1.380 |
Why?
|
| Case-Control Studies | 34 | 2022 | 638 | 1.350 |
Why?
|
| Bacterial Translocation | 12 | 2021 | 33 | 1.330 |
Why?
|
| Cytomegalovirus | 14 | 2020 | 76 | 1.320 |
Why?
|
| HIV Seronegativity | 17 | 2015 | 43 | 1.290 |
Why?
|
| Bacteria | 7 | 2018 | 77 | 1.280 |
Why?
|
| Mucous Membrane | 10 | 2015 | 40 | 1.240 |
Why?
|
| AIDS Vaccines | 10 | 2022 | 14 | 1.180 |
Why?
|
| Coinfection | 8 | 2016 | 29 | 1.170 |
Why?
|
| Receptors, CXCR4 | 11 | 2019 | 27 | 1.160 |
Why?
|
| Immunoglobulin G | 15 | 2023 | 129 | 1.150 |
Why?
|
| Toll-Like Receptors | 6 | 2014 | 28 | 1.150 |
Why?
|
| Receptors, CCR5 | 14 | 2008 | 27 | 1.140 |
Why?
|
| Cardiovascular Diseases | 14 | 2023 | 402 | 1.130 |
Why?
|
| Cohort Studies | 42 | 2024 | 1939 | 1.130 |
Why?
|
| Hepatitis C, Chronic | 10 | 2017 | 78 | 1.130 |
Why?
|
| GB virus C | 4 | 2013 | 6 | 1.130 |
Why?
|
| Vaginosis, Bacterial | 12 | 2017 | 30 | 1.110 |
Why?
|
| Interleukins | 7 | 2023 | 37 | 1.110 |
Why?
|
| B-Lymphocytes, Regulatory | 4 | 2017 | 7 | 1.110 |
Why?
|
| Interleukin-10 | 12 | 2017 | 36 | 1.100 |
Why?
|
| Gene Expression Profiling | 9 | 2022 | 153 | 1.080 |
Why?
|
| Simian Immunodeficiency Virus | 11 | 2023 | 22 | 1.050 |
Why?
|
| Young Adult | 34 | 2021 | 1932 | 1.040 |
Why?
|
| Flaviviridae Infections | 3 | 2013 | 5 | 1.010 |
Why?
|
| Hepatitis, Viral, Human | 5 | 2013 | 8 | 1.010 |
Why?
|
| HIV Protease Inhibitors | 15 | 2020 | 21 | 1.000 |
Why?
|
| Neoplasms | 11 | 2021 | 247 | 0.990 |
Why?
|
| Plasma | 9 | 2019 | 34 | 0.970 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2020 | 18 | 0.960 |
Why?
|
| Host-Pathogen Interactions | 7 | 2022 | 22 | 0.960 |
Why?
|
| Aged | 51 | 2023 | 9448 | 0.930 |
Why?
|
| RNA, Ribosomal, 16S | 11 | 2021 | 56 | 0.920 |
Why?
|
| Interleukin-2 | 22 | 2016 | 66 | 0.920 |
Why?
|
| DNA, Viral | 23 | 2021 | 96 | 0.920 |
Why?
|
| Phenotype | 31 | 2023 | 355 | 0.910 |
Why?
|
| Disease Progression | 22 | 2023 | 787 | 0.910 |
Why?
|
| Hepatitis C | 8 | 2016 | 65 | 0.910 |
Why?
|
| Frailty | 4 | 2024 | 38 | 0.900 |
Why?
|
| Viral Vaccines | 2 | 2022 | 5 | 0.900 |
Why?
|
| Prospective Studies | 34 | 2023 | 1811 | 0.870 |
Why?
|
| Signal Transduction | 8 | 2022 | 482 | 0.860 |
Why?
|
| Macrophages | 13 | 2021 | 128 | 0.860 |
Why?
|
| Plaque, Atherosclerotic | 8 | 2023 | 25 | 0.860 |
Why?
|
| Sexually Transmitted Diseases | 6 | 2016 | 16 | 0.860 |
Why?
|
| Homeostasis | 5 | 2017 | 82 | 0.850 |
Why?
|
| Carotid Stenosis | 4 | 2023 | 22 | 0.850 |
Why?
|
| T-Lymphocytes, Cytotoxic | 11 | 2016 | 35 | 0.840 |
Why?
|
| Virology | 2 | 2020 | 14 | 0.840 |
Why?
|
| Cross-Sectional Studies | 30 | 2022 | 959 | 0.830 |
Why?
|
| Viremia | 14 | 2020 | 36 | 0.820 |
Why?
|
| HIV Antibodies | 18 | 2017 | 42 | 0.810 |
Why?
|
| Adolescent | 39 | 2016 | 2279 | 0.800 |
Why?
|
| Food Hypersensitivity | 3 | 2021 | 57 | 0.800 |
Why?
|
| Immune System | 6 | 2011 | 20 | 0.800 |
Why?
|
| Reverse Transcriptase Inhibitors | 12 | 2010 | 24 | 0.780 |
Why?
|
| Interleukin-7 | 9 | 2017 | 19 | 0.770 |
Why?
|
| Immunologic Memory | 11 | 2022 | 35 | 0.760 |
Why?
|
| Zidovudine | 23 | 2003 | 39 | 0.760 |
Why?
|
| Lipopolysaccharide Receptors | 11 | 2022 | 27 | 0.750 |
Why?
|
| Diabetes Mellitus | 5 | 2022 | 138 | 0.750 |
Why?
|
| HIV Long-Term Survivors | 4 | 2021 | 10 | 0.740 |
Why?
|
| Cells, Cultured | 29 | 2018 | 676 | 0.740 |
Why?
|
| Dermatitis, Atopic | 4 | 2021 | 19 | 0.720 |
Why?
|
| Pregnancy Complications, Infectious | 9 | 2003 | 30 | 0.720 |
Why?
|
| Polymerase Chain Reaction | 15 | 2017 | 161 | 0.710 |
Why?
|
| B-Lymphocyte Subsets | 2 | 2017 | 6 | 0.710 |
Why?
|
| Cyclohexanes | 6 | 2017 | 7 | 0.700 |
Why?
|
| Influenza A virus | 3 | 2018 | 20 | 0.690 |
Why?
|
| Interleukin-12 | 9 | 2016 | 38 | 0.690 |
Why?
|
| Ritonavir | 13 | 2019 | 18 | 0.690 |
Why?
|
| Triazoles | 6 | 2017 | 29 | 0.690 |
Why?
|
| Inflammation Mediators | 8 | 2021 | 83 | 0.690 |
Why?
|
| Influenza Vaccines | 2 | 2018 | 11 | 0.690 |
Why?
|
| Immunity, Cellular | 14 | 2020 | 65 | 0.670 |
Why?
|
| Body Fluids | 5 | 2016 | 19 | 0.670 |
Why?
|
| Immunologic Factors | 7 | 2019 | 39 | 0.670 |
Why?
|
| Fungi | 2 | 2017 | 5 | 0.670 |
Why?
|
| Lactobacillus | 8 | 2016 | 19 | 0.670 |
Why?
|
| Glycogen | 5 | 2016 | 12 | 0.670 |
Why?
|
| Hepacivirus | 8 | 2016 | 73 | 0.660 |
Why?
|
| Toll-Like Receptor 2 | 2 | 2015 | 32 | 0.650 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2015 | 42 | 0.650 |
Why?
|
| Microbial Interactions | 1 | 2017 | 1 | 0.640 |
Why?
|
| Animals | 33 | 2023 | 4552 | 0.640 |
Why?
|
| Apoptosis | 8 | 2014 | 251 | 0.630 |
Why?
|
| Adaptive Immunity | 2 | 2020 | 15 | 0.630 |
Why?
|
| Cocaine | 3 | 2022 | 46 | 0.620 |
Why?
|
| Influenza, Human | 1 | 2018 | 46 | 0.620 |
Why?
|
| Liver Cirrhosis | 5 | 2016 | 60 | 0.620 |
Why?
|
| HLA-DR Antigens | 16 | 2013 | 26 | 0.610 |
Why?
|
| Interferon-gamma | 17 | 2018 | 109 | 0.610 |
Why?
|
| Blood Coagulation | 2 | 2014 | 21 | 0.600 |
Why?
|
| Carotid Arteries | 11 | 2023 | 54 | 0.600 |
Why?
|
| Papillomavirus Infections | 3 | 2014 | 37 | 0.590 |
Why?
|
| Receptors, Antigen, T-Cell | 8 | 2013 | 29 | 0.590 |
Why?
|
| Immunotherapy | 6 | 2020 | 62 | 0.590 |
Why?
|
| HIV Antigens | 12 | 2016 | 22 | 0.580 |
Why?
|
| Drug Therapy, Combination | 22 | 2019 | 241 | 0.570 |
Why?
|
| Colon | 5 | 2018 | 148 | 0.560 |
Why?
|
| CD4-CD8 Ratio | 11 | 2019 | 16 | 0.560 |
Why?
|
| Osteoporosis | 2 | 2016 | 80 | 0.550 |
Why?
|
| Lymphocyte Count | 18 | 2017 | 35 | 0.550 |
Why?
|
| Immunoassay | 5 | 2011 | 41 | 0.540 |
Why?
|
| Fractures, Bone | 1 | 2016 | 73 | 0.530 |
Why?
|
| Benzoxazines | 4 | 2019 | 9 | 0.520 |
Why?
|
| Intestines | 5 | 2021 | 107 | 0.520 |
Why?
|
| ADP-ribosyl Cyclase 1 | 11 | 2017 | 18 | 0.500 |
Why?
|
| Membrane Proteins | 2 | 2017 | 173 | 0.500 |
Why?
|
| CD8 Antigens | 9 | 2013 | 18 | 0.490 |
Why?
|
| Epithelial Cells | 1 | 2014 | 87 | 0.480 |
Why?
|
| Lactoferrin | 2 | 2011 | 12 | 0.480 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2021 | 100 | 0.480 |
Why?
|
| Interleukin-1beta | 2 | 2011 | 55 | 0.480 |
Why?
|
| DNA, Bacterial | 8 | 2017 | 48 | 0.480 |
Why?
|
| Glucose Transporter Type 1 | 4 | 2018 | 7 | 0.480 |
Why?
|
| Cell Differentiation | 8 | 2021 | 146 | 0.480 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 51 | 0.470 |
Why?
|
| United States | 20 | 2022 | 2333 | 0.460 |
Why?
|
| Vaccines | 2 | 2023 | 12 | 0.460 |
Why?
|
| Toll-Like Receptor 7 | 3 | 2011 | 5 | 0.460 |
Why?
|
| CD4 Antigens | 12 | 2013 | 35 | 0.450 |
Why?
|
| Tuberculosis | 2 | 2023 | 25 | 0.450 |
Why?
|
| Antigen-Presenting Cells | 4 | 2014 | 16 | 0.450 |
Why?
|
| Imidazoles | 2 | 2016 | 72 | 0.440 |
Why?
|
| Receptors, Tumor Necrosis Factor | 3 | 2010 | 33 | 0.440 |
Why?
|
| Menstrual Cycle | 7 | 2015 | 27 | 0.440 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 4 | 2022 | 8 | 0.440 |
Why?
|
| Thromboplastin | 3 | 2019 | 5 | 0.440 |
Why?
|
| Receptors, IgG | 7 | 2021 | 19 | 0.440 |
Why?
|
| Metagenome | 6 | 2021 | 22 | 0.430 |
Why?
|
| Genital Diseases, Female | 3 | 2008 | 10 | 0.430 |
Why?
|
| Antigens, Surface | 13 | 2003 | 26 | 0.430 |
Why?
|
| Withholding Treatment | 3 | 2021 | 7 | 0.430 |
Why?
|
| Saliva | 5 | 2015 | 53 | 0.430 |
Why?
|
| Anti-Infective Agents | 1 | 2012 | 63 | 0.430 |
Why?
|
| Antibody Formation | 4 | 2022 | 40 | 0.430 |
Why?
|
| Infectious Disease Transmission, Vertical | 5 | 2005 | 19 | 0.430 |
Why?
|
| Cocaine-Related Disorders | 2 | 2022 | 18 | 0.420 |
Why?
|
| Caspase 3 | 2 | 2016 | 30 | 0.410 |
Why?
|
| Risk Factors | 20 | 2024 | 2443 | 0.410 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 7 | 2015 | 16 | 0.410 |
Why?
|
| Interferon-alpha | 7 | 2012 | 66 | 0.410 |
Why?
|
| Thymus Gland | 6 | 2014 | 21 | 0.410 |
Why?
|
| Biopsy | 6 | 2019 | 234 | 0.410 |
Why?
|
| Pilot Projects | 10 | 2019 | 394 | 0.410 |
Why?
|
| Oligodeoxyribonucleotides | 3 | 2009 | 10 | 0.410 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2023 | 63 | 0.410 |
Why?
|
| Receptors, Cell Surface | 7 | 2015 | 50 | 0.400 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 10 | 2017 | 130 | 0.400 |
Why?
|
| Pyrimidinones | 2 | 2010 | 4 | 0.400 |
Why?
|
| Sequence Analysis, DNA | 8 | 2017 | 73 | 0.390 |
Why?
|
| Antigens, Differentiation | 8 | 2017 | 20 | 0.390 |
Why?
|
| Membrane Glycoproteins | 11 | 2017 | 101 | 0.390 |
Why?
|
| Vaginal Douching | 4 | 2014 | 9 | 0.390 |
Why?
|
| Leukocyte Count | 12 | 2002 | 92 | 0.390 |
Why?
|
| Antiviral Agents | 7 | 2016 | 132 | 0.380 |
Why?
|
| Symbiosis | 3 | 2020 | 5 | 0.370 |
Why?
|
| CD56 Antigen | 4 | 2017 | 8 | 0.370 |
Why?
|
| Antibodies, Neutralizing | 4 | 2023 | 27 | 0.370 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2009 | 1 | 0.370 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2009 | 18 | 0.360 |
Why?
|
| Vascular Stiffness | 3 | 2023 | 9 | 0.360 |
Why?
|
| Tumor Necrosis Factor-alpha | 8 | 2011 | 215 | 0.360 |
Why?
|
| Chronic Disease | 9 | 2016 | 495 | 0.360 |
Why?
|
| Cell Proliferation | 8 | 2018 | 201 | 0.360 |
Why?
|
| Chloroquine | 3 | 2016 | 12 | 0.360 |
Why?
|
| Cell Division | 10 | 2009 | 113 | 0.350 |
Why?
|
| Longitudinal Studies | 13 | 2022 | 1442 | 0.350 |
Why?
|
| NF-kappa B | 5 | 2022 | 107 | 0.350 |
Why?
|
| Infant, Newborn, Diseases | 3 | 2005 | 17 | 0.340 |
Why?
|
| Interleukin-17 | 4 | 2021 | 27 | 0.340 |
Why?
|
| RNA, Messenger | 7 | 2021 | 323 | 0.340 |
Why?
|
| Galectins | 2 | 2021 | 6 | 0.340 |
Why?
|
| Aged, 80 and over | 15 | 2021 | 4851 | 0.340 |
Why?
|
| Carotid Intima-Media Thickness | 5 | 2021 | 24 | 0.330 |
Why?
|
| Raltegravir Potassium | 3 | 2017 | 9 | 0.330 |
Why?
|
| Diet | 3 | 2018 | 174 | 0.330 |
Why?
|
| Mycobacterium tuberculosis | 3 | 2022 | 18 | 0.330 |
Why?
|
| Biomedical Research | 2 | 2020 | 81 | 0.330 |
Why?
|
| Tenofovir | 3 | 2019 | 4 | 0.330 |
Why?
|
| Time Factors | 16 | 2021 | 1616 | 0.330 |
Why?
|
| Infant | 11 | 2021 | 531 | 0.330 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2008 | 2 | 0.330 |
Why?
|
| Pregnancy | 11 | 2004 | 403 | 0.330 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2008 | 8 | 0.330 |
Why?
|
| Quinolines | 1 | 2008 | 16 | 0.330 |
Why?
|
| Virus Latency | 5 | 2021 | 17 | 0.330 |
Why?
|
| Interleukin-8 | 4 | 2015 | 32 | 0.320 |
Why?
|
| HIV Integrase Inhibitors | 2 | 2019 | 6 | 0.320 |
Why?
|
| CD28 Antigens | 8 | 2022 | 16 | 0.320 |
Why?
|
| DNA | 7 | 2018 | 125 | 0.320 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 8 | 2006 | 17 | 0.320 |
Why?
|
| Toll-Like Receptor 9 | 3 | 2017 | 10 | 0.300 |
Why?
|
| Risk-Taking | 1 | 2007 | 32 | 0.300 |
Why?
|
| Fatty Acids, Volatile | 2 | 2021 | 30 | 0.300 |
Why?
|
| Glucose | 3 | 2022 | 59 | 0.300 |
Why?
|
| Lamivudine | 11 | 2007 | 18 | 0.300 |
Why?
|
| Vaccination | 6 | 2023 | 41 | 0.300 |
Why?
|
| Ileum | 2 | 2017 | 22 | 0.290 |
Why?
|
| Specimen Handling | 3 | 2008 | 48 | 0.290 |
Why?
|
| Lymphoid Tissue | 5 | 2017 | 18 | 0.290 |
Why?
|
| Interferon Type I | 3 | 2018 | 18 | 0.290 |
Why?
|
| Clinical Laboratory Techniques | 4 | 2011 | 34 | 0.280 |
Why?
|
| HIV Core Protein p24 | 10 | 2007 | 29 | 0.270 |
Why?
|
| Trichomonas vaginalis | 3 | 2015 | 4 | 0.270 |
Why?
|
| Antibodies, Monoclonal | 18 | 2007 | 260 | 0.270 |
Why?
|
| Interleukin-4 | 4 | 2022 | 35 | 0.270 |
Why?
|
| DNA, Ribosomal | 5 | 2017 | 12 | 0.270 |
Why?
|
| Health Services Accessibility | 2 | 2022 | 101 | 0.270 |
Why?
|
| Adjuvants, Immunologic | 5 | 2018 | 26 | 0.260 |
Why?
|
| C-Reactive Protein | 7 | 2010 | 125 | 0.260 |
Why?
|
| Myocardial Infarction | 3 | 2021 | 172 | 0.260 |
Why?
|
| Age Factors | 8 | 2018 | 843 | 0.260 |
Why?
|
| B7-H1 Antigen | 3 | 2014 | 13 | 0.260 |
Why?
|
| Infant, Newborn | 12 | 2006 | 604 | 0.260 |
Why?
|
| Gastrointestinal Tract | 3 | 2021 | 55 | 0.260 |
Why?
|
| Neutralization Tests | 3 | 2022 | 10 | 0.260 |
Why?
|
| Immunity | 5 | 2019 | 24 | 0.260 |
Why?
|
| Cryopreservation | 2 | 2006 | 24 | 0.260 |
Why?
|
| Risk Assessment | 5 | 2021 | 679 | 0.260 |
Why?
|
| Immune Tolerance | 2 | 2013 | 22 | 0.260 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 7 | 2023 | 28 | 0.250 |
Why?
|
| Semen | 2 | 2008 | 5 | 0.250 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 13 | 2017 | 24 | 0.250 |
Why?
|
| Polyamines | 2 | 2014 | 2 | 0.250 |
Why?
|
| Comorbidity | 7 | 2022 | 498 | 0.250 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 2018 | 13 | 0.250 |
Why?
|
| Rectum | 3 | 2019 | 61 | 0.250 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2014 | 145 | 0.250 |
Why?
|
| Trichomonas Vaginitis | 2 | 2015 | 3 | 0.240 |
Why?
|
| Up-Regulation | 9 | 2019 | 174 | 0.240 |
Why?
|
| Transcriptome | 2 | 2022 | 83 | 0.240 |
Why?
|
| Mice | 10 | 2023 | 1607 | 0.240 |
Why?
|
| Serotonin | 1 | 2023 | 40 | 0.240 |
Why?
|
| Peptide Fragments | 3 | 2018 | 99 | 0.240 |
Why?
|
| Gene Expression Regulation, Viral | 4 | 1999 | 14 | 0.240 |
Why?
|
| Progesterone | 4 | 2016 | 26 | 0.240 |
Why?
|
| Stroke | 3 | 2022 | 293 | 0.230 |
Why?
|
| AIDS Dementia Complex | 3 | 2019 | 41 | 0.230 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 3 | 2013 | 7 | 0.230 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 2 | 2023 | 41 | 0.230 |
Why?
|
| HIV Envelope Protein gp41 | 3 | 2017 | 12 | 0.230 |
Why?
|
| Hip Fractures | 1 | 2023 | 32 | 0.230 |
Why?
|
| GPI-Linked Proteins | 4 | 2021 | 25 | 0.230 |
Why?
|
| Base Sequence | 10 | 2014 | 134 | 0.230 |
Why?
|
| Rhinitis | 2 | 2016 | 165 | 0.230 |
Why?
|
| Substance-Related Disorders | 2 | 2003 | 104 | 0.230 |
Why?
|
| Interleukin-15 | 3 | 2011 | 11 | 0.230 |
Why?
|
| Tuberculosis Vaccines | 1 | 2022 | 2 | 0.220 |
Why?
|
| Kynurenine | 2 | 2022 | 3 | 0.220 |
Why?
|
| Tryptophan | 2 | 2023 | 15 | 0.220 |
Why?
|
| Duodenum | 2 | 2019 | 12 | 0.220 |
Why?
|
| Dideoxynucleosides | 3 | 2010 | 4 | 0.220 |
Why?
|
| Chemokine CCL5 | 4 | 2008 | 17 | 0.220 |
Why?
|
| Herpesvirus 4, Human | 3 | 2020 | 13 | 0.220 |
Why?
|
| Sinusitis | 2 | 2016 | 187 | 0.220 |
Why?
|
| Pandemics | 2 | 2022 | 236 | 0.220 |
Why?
|
| Cell Separation | 8 | 2015 | 42 | 0.220 |
Why?
|
| Viral Envelope Proteins | 4 | 2013 | 21 | 0.220 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 1830 | 0.220 |
Why?
|
| beta-Glucans | 1 | 2022 | 25 | 0.220 |
Why?
|
| Complement System Proteins | 5 | 1999 | 15 | 0.220 |
Why?
|
| Podocytes | 1 | 2023 | 85 | 0.220 |
Why?
|
| Coculture Techniques | 4 | 2014 | 37 | 0.210 |
Why?
|
| Trophoblasts | 1 | 2002 | 3 | 0.210 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2020 | 29 | 0.210 |
Why?
|
| CD3 Complex | 6 | 2006 | 13 | 0.210 |
Why?
|
| Virus Shedding | 5 | 2016 | 13 | 0.210 |
Why?
|
| Methamphetamine | 1 | 2022 | 48 | 0.210 |
Why?
|
| Developing Countries | 4 | 2014 | 22 | 0.210 |
Why?
|
| Continuity of Patient Care | 1 | 2022 | 28 | 0.210 |
Why?
|
| CD57 Antigens | 3 | 2017 | 5 | 0.210 |
Why?
|
| Succinic Acid | 1 | 2021 | 1 | 0.210 |
Why?
|
| Th17 Cells | 2 | 2021 | 28 | 0.210 |
Why?
|
| Recombinant Proteins | 11 | 2019 | 251 | 0.210 |
Why?
|
| Protein Isoforms | 4 | 2023 | 53 | 0.210 |
Why?
|
| Sex Factors | 5 | 2021 | 496 | 0.200 |
Why?
|
| Caproates | 1 | 2021 | 1 | 0.200 |
Why?
|
| Adipose Tissue | 2 | 2019 | 73 | 0.200 |
Why?
|
| Laboratories | 3 | 2008 | 25 | 0.200 |
Why?
|
| Asymptomatic Diseases | 4 | 2019 | 18 | 0.200 |
Why?
|
| Colon, Sigmoid | 2 | 2020 | 18 | 0.200 |
Why?
|
| Sex Characteristics | 1 | 2022 | 132 | 0.200 |
Why?
|
| Phospholipids | 1 | 2021 | 7 | 0.200 |
Why?
|
| Intraepithelial Lymphocytes | 1 | 2021 | 1 | 0.200 |
Why?
|
| Double-Blind Method | 8 | 2019 | 503 | 0.200 |
Why?
|
| CD11b Antigen | 1 | 2021 | 17 | 0.200 |
Why?
|
| Schistosomiasis | 1 | 2021 | 8 | 0.200 |
Why?
|
| Neurocognitive Disorders | 2 | 2018 | 19 | 0.200 |
Why?
|
| Cell Line, Tumor | 2 | 2014 | 264 | 0.200 |
Why?
|
| Child, Preschool | 7 | 2021 | 642 | 0.200 |
Why?
|
| In Vitro Techniques | 11 | 2004 | 213 | 0.200 |
Why?
|
| Down-Regulation | 4 | 2019 | 112 | 0.190 |
Why?
|
| Sulfonamides | 2 | 2012 | 54 | 0.190 |
Why?
|
| Menopause | 1 | 2022 | 134 | 0.190 |
Why?
|
| Palatine Tonsil | 3 | 2000 | 7 | 0.190 |
Why?
|
| Virus Activation | 2 | 2021 | 11 | 0.190 |
Why?
|
| Sexual and Gender Minorities | 1 | 2021 | 25 | 0.190 |
Why?
|
| Body Mass Index | 3 | 2019 | 428 | 0.190 |
Why?
|
| Incidence | 5 | 2023 | 756 | 0.190 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2020 | 2 | 0.190 |
Why?
|
| Immunoglobulin A | 3 | 2017 | 19 | 0.190 |
Why?
|
| Models, Animal | 2 | 2012 | 126 | 0.190 |
Why?
|
| Leukocyte Common Antigens | 7 | 2006 | 11 | 0.190 |
Why?
|
| Treatment Outcome | 13 | 2019 | 3478 | 0.190 |
Why?
|
| Inflammasomes | 1 | 2020 | 15 | 0.190 |
Why?
|
| Fluorescent Antibody Technique | 8 | 2007 | 78 | 0.190 |
Why?
|
| Occupational Exposure | 6 | 1999 | 25 | 0.180 |
Why?
|
| Immune Reconstitution | 1 | 2019 | 1 | 0.180 |
Why?
|
| Lung | 1 | 2021 | 154 | 0.180 |
Why?
|
| Congresses as Topic | 1 | 2020 | 33 | 0.180 |
Why?
|
| Diet, High-Fat | 1 | 2019 | 17 | 0.180 |
Why?
|
| Diabetes Complications | 1 | 2020 | 64 | 0.180 |
Why?
|
| Immunity, Humoral | 2 | 2017 | 6 | 0.180 |
Why?
|
| Health Personnel | 5 | 2022 | 115 | 0.180 |
Why?
|
| Drug Resistance, Viral | 4 | 2012 | 37 | 0.180 |
Why?
|
| Staining and Labeling | 3 | 2014 | 22 | 0.180 |
Why?
|
| Sitagliptin Phosphate | 1 | 2019 | 1 | 0.180 |
Why?
|
| Cell Communication | 2 | 2012 | 29 | 0.180 |
Why?
|
| Complement Activation | 7 | 2021 | 13 | 0.180 |
Why?
|
| Disease | 1 | 2019 | 7 | 0.180 |
Why?
|
| Cells | 1 | 2019 | 4 | 0.180 |
Why?
|
| Postpartum Period | 2 | 1999 | 24 | 0.180 |
Why?
|
| Receptors, CXCR5 | 2 | 2016 | 2 | 0.180 |
Why?
|
| Coronary Disease | 1 | 2020 | 86 | 0.180 |
Why?
|
| Ultrasonography | 6 | 2019 | 226 | 0.180 |
Why?
|
| Blood Pressure | 1 | 2021 | 238 | 0.180 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2019 | 36 | 0.180 |
Why?
|
| Carnitine | 1 | 2019 | 7 | 0.180 |
Why?
|
| Cell Line | 14 | 2018 | 298 | 0.180 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 2 | 2017 | 5 | 0.180 |
Why?
|
| Leukocytes | 3 | 2015 | 43 | 0.180 |
Why?
|
| Bone Resorption | 2 | 2019 | 104 | 0.180 |
Why?
|
| Ceramides | 1 | 2019 | 14 | 0.180 |
Why?
|
| Estrogens | 2 | 2016 | 33 | 0.180 |
Why?
|
| Proviruses | 6 | 2000 | 9 | 0.180 |
Why?
|
| Antigens, Viral | 8 | 2010 | 19 | 0.170 |
Why?
|
| Disease Models, Animal | 4 | 2018 | 724 | 0.170 |
Why?
|
| Therapeutic Irrigation | 7 | 2014 | 66 | 0.170 |
Why?
|
| Lipopolysaccharides | 7 | 2014 | 127 | 0.170 |
Why?
|
| Central Nervous System | 1 | 2019 | 57 | 0.170 |
Why?
|
| Didanosine | 2 | 1998 | 6 | 0.170 |
Why?
|
| Immunomodulation | 1 | 2019 | 8 | 0.170 |
Why?
|
| Sensitivity and Specificity | 7 | 2022 | 553 | 0.170 |
Why?
|
| Chemokines | 3 | 2012 | 29 | 0.170 |
Why?
|
| Decision Making | 1 | 2021 | 220 | 0.170 |
Why?
|
| Premenopause | 2 | 2016 | 20 | 0.170 |
Why?
|
| Food Supply | 1 | 2019 | 14 | 0.170 |
Why?
|
| CCR5 Receptor Antagonists | 2 | 2016 | 2 | 0.170 |
Why?
|
| Methylamines | 1 | 2018 | 4 | 0.170 |
Why?
|
| Receptors, Fc | 3 | 2021 | 11 | 0.170 |
Why?
|
| Apolipoprotein B-100 | 1 | 2018 | 1 | 0.170 |
Why?
|
| Apolipoproteins B | 1 | 2018 | 3 | 0.170 |
Why?
|
| Extracellular Vesicles | 1 | 2018 | 3 | 0.170 |
Why?
|
| Choline | 1 | 2018 | 7 | 0.170 |
Why?
|
| Child | 7 | 2021 | 1346 | 0.170 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 16 | 0.170 |
Why?
|
| Biodiversity | 3 | 2020 | 37 | 0.170 |
Why?
|
| Vitamin D | 1 | 2019 | 31 | 0.170 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 148 | 0.170 |
Why?
|
| Drug Administration Schedule | 6 | 2012 | 223 | 0.170 |
Why?
|
| Chemokine CXCL10 | 4 | 2015 | 8 | 0.170 |
Why?
|
| Sexual Behavior | 4 | 2014 | 66 | 0.170 |
Why?
|
| Hypertension | 1 | 2021 | 266 | 0.160 |
Why?
|
| Galactose | 1 | 2018 | 3 | 0.160 |
Why?
|
| Lipids | 2 | 2023 | 36 | 0.160 |
Why?
|
| Rifamycins | 2 | 2016 | 2 | 0.160 |
Why?
|
| PAX5 Transcription Factor | 1 | 2018 | 2 | 0.160 |
Why?
|
| Fatigue Syndrome, Chronic | 3 | 1994 | 7 | 0.160 |
Why?
|
| Sustained Virologic Response | 1 | 2018 | 8 | 0.160 |
Why?
|
| Transcriptional Activation | 1 | 1998 | 23 | 0.160 |
Why?
|
| Wnt Signaling Pathway | 1 | 2018 | 30 | 0.160 |
Why?
|
| Biological Therapy | 1 | 2018 | 5 | 0.160 |
Why?
|
| Herpesvirus 2, Human | 1 | 2017 | 1 | 0.160 |
Why?
|
| Herpes Genitalis | 1 | 2017 | 3 | 0.160 |
Why?
|
| Drug Discovery | 1 | 2018 | 20 | 0.160 |
Why?
|
| Ulcer | 1 | 2017 | 7 | 0.160 |
Why?
|
| alpha-Amylases | 2 | 2015 | 3 | 0.160 |
Why?
|
| Antibodies | 5 | 2023 | 65 | 0.160 |
Why?
|
| Autoimmunity | 1 | 2017 | 19 | 0.160 |
Why?
|
| Bone and Bones | 1 | 2018 | 119 | 0.160 |
Why?
|
| Alkynes | 4 | 2019 | 9 | 0.160 |
Why?
|
| Clinical Trials as Topic | 6 | 2015 | 324 | 0.150 |
Why?
|
| Cyclopropanes | 4 | 2019 | 25 | 0.150 |
Why?
|
| Dietary Fiber | 1 | 2017 | 22 | 0.150 |
Why?
|
| Cytotoxicity, Immunologic | 6 | 1990 | 29 | 0.150 |
Why?
|
| Cholesterol, LDL | 2 | 2014 | 30 | 0.150 |
Why?
|
| Cell Cycle | 5 | 2012 | 41 | 0.150 |
Why?
|
| Virus Diseases | 3 | 2023 | 17 | 0.150 |
Why?
|
| Metabolomics | 3 | 2021 | 23 | 0.150 |
Why?
|
| Butyrates | 1 | 2017 | 19 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 200 | 0.150 |
Why?
|
| Valproic Acid | 2 | 2008 | 30 | 0.150 |
Why?
|
| Kidney | 1 | 2018 | 173 | 0.150 |
Why?
|
| Asthma | 2 | 2016 | 138 | 0.150 |
Why?
|
| Reproducibility of Results | 9 | 2014 | 788 | 0.150 |
Why?
|
| Arenaviridae Infections | 1 | 2016 | 2 | 0.150 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2016 | 2 | 0.150 |
Why?
|
| Smoking | 4 | 2023 | 194 | 0.150 |
Why?
|
| Multivariate Analysis | 6 | 2019 | 324 | 0.150 |
Why?
|
| Receptors, HIV | 4 | 2017 | 6 | 0.150 |
Why?
|
| Global Health | 2 | 2006 | 55 | 0.140 |
Why?
|
| Cholesterol, HDL | 2 | 2013 | 27 | 0.140 |
Why?
|
| Australia | 2 | 2014 | 44 | 0.140 |
Why?
|
| Child Health | 1 | 2016 | 6 | 0.140 |
Why?
|
| Loneliness | 1 | 2017 | 52 | 0.140 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2016 | 30 | 0.140 |
Why?
|
| Education | 1 | 2016 | 39 | 0.140 |
Why?
|
| Viral Tropism | 1 | 2016 | 3 | 0.140 |
Why?
|
| Vaccines, DNA | 1 | 2016 | 6 | 0.140 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 521 | 0.140 |
Why?
|
| Antibody Specificity | 3 | 2021 | 50 | 0.140 |
Why?
|
| Neutrophils | 4 | 2011 | 117 | 0.140 |
Why?
|
| Thrombophilia | 1 | 2016 | 7 | 0.140 |
Why?
|
| Transcription, Genetic | 5 | 2019 | 108 | 0.140 |
Why?
|
| Nasal Mucosa | 1 | 2016 | 16 | 0.140 |
Why?
|
| Cognitive Aging | 1 | 2017 | 81 | 0.140 |
Why?
|
| Multicenter Studies as Topic | 4 | 2019 | 75 | 0.140 |
Why?
|
| Macrophage Inflammatory Proteins | 4 | 2011 | 9 | 0.140 |
Why?
|
| Osteogenesis | 1 | 2016 | 96 | 0.140 |
Why?
|
| Propidium | 2 | 2014 | 4 | 0.130 |
Why?
|
| Linear Models | 4 | 2019 | 254 | 0.130 |
Why?
|
| Prognosis | 6 | 2021 | 840 | 0.130 |
Why?
|
| Macaca nemestrina | 4 | 2017 | 4 | 0.130 |
Why?
|
| Postmenopause | 1 | 2015 | 61 | 0.130 |
Why?
|
| Metagenomics | 3 | 2021 | 6 | 0.130 |
Why?
|
| Models, Biological | 3 | 2013 | 343 | 0.130 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2015 | 12 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2015 | 42 | 0.130 |
Why?
|
| Hepatitis B, Chronic | 1 | 2015 | 6 | 0.130 |
Why?
|
| Regression Analysis | 3 | 2020 | 298 | 0.130 |
Why?
|
| Quality Control | 6 | 1994 | 43 | 0.130 |
Why?
|
| Nasal Polyps | 1 | 2016 | 62 | 0.130 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2014 | 2 | 0.130 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2014 | 11 | 0.130 |
Why?
|
| Genes, env | 3 | 2011 | 5 | 0.130 |
Why?
|
| HIV Long Terminal Repeat | 4 | 1999 | 16 | 0.130 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2012 | 33 | 0.130 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 1988 | 34 | 0.130 |
Why?
|
| Caspases | 1 | 2014 | 32 | 0.130 |
Why?
|
| Antibodies, Bacterial | 1 | 2014 | 22 | 0.130 |
Why?
|
| Hypersensitivity, Delayed | 4 | 2003 | 21 | 0.130 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2014 | 2 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 402 | 0.130 |
Why?
|
| Arthritis, Rheumatoid | 4 | 1996 | 358 | 0.130 |
Why?
|
| Lipoproteins, LDL | 1 | 2014 | 5 | 0.130 |
Why?
|
| CD40 Ligand | 2 | 2013 | 8 | 0.130 |
Why?
|
| Receptors, Interleukin-10 | 1 | 2014 | 2 | 0.130 |
Why?
|
| Homosexuality | 3 | 1990 | 9 | 0.130 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 6 | 2007 | 6 | 0.130 |
Why?
|
| Solubility | 7 | 2015 | 36 | 0.120 |
Why?
|
| Dried Blood Spot Testing | 1 | 2014 | 4 | 0.120 |
Why?
|
| Antigens | 2 | 1998 | 26 | 0.120 |
Why?
|
| Bone Density | 1 | 2015 | 134 | 0.120 |
Why?
|
| Cardiovascular Agents | 1 | 2014 | 28 | 0.120 |
Why?
|
| Molecular Sequence Data | 9 | 2003 | 246 | 0.120 |
Why?
|
| Cellular Senescence | 2 | 2011 | 18 | 0.120 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2009 | 16 | 0.120 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 37 | 0.120 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2000 | 46 | 0.120 |
Why?
|
| Cytological Techniques | 1 | 1993 | 14 | 0.120 |
Why?
|
| Aging, Premature | 1 | 2013 | 1 | 0.120 |
Why?
|
| Phylogeny | 5 | 2017 | 63 | 0.120 |
Why?
|
| Early Diagnosis | 1 | 2014 | 65 | 0.120 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2013 | 4 | 0.120 |
Why?
|
| Writing | 1 | 1994 | 20 | 0.120 |
Why?
|
| Endotoxemia | 1 | 2014 | 29 | 0.120 |
Why?
|
| Th2 Cells | 2 | 2007 | 27 | 0.120 |
Why?
|
| Hydrogen-Ion Concentration | 4 | 2016 | 148 | 0.120 |
Why?
|
| Ligands | 3 | 2011 | 55 | 0.120 |
Why?
|
| Gene Products, gag | 2 | 2006 | 4 | 0.120 |
Why?
|
| Glioma | 3 | 1983 | 47 | 0.120 |
Why?
|
| Receptors, Interleukin-2 | 4 | 2006 | 10 | 0.120 |
Why?
|
| Trichomonas Infections | 1 | 2013 | 3 | 0.120 |
Why?
|
| Rwanda | 2 | 2014 | 3 | 0.120 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1993 | 16 | 0.110 |
Why?
|
| Genes, pol | 2 | 2003 | 3 | 0.110 |
Why?
|
| Cytoplasm | 1 | 1993 | 35 | 0.110 |
Why?
|
| Hospitalization | 1 | 2016 | 317 | 0.110 |
Why?
|
| Cause of Death | 1 | 2013 | 65 | 0.110 |
Why?
|
| Graft vs Host Disease | 1 | 2013 | 45 | 0.110 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2012 | 3 | 0.110 |
Why?
|
| Lymphoproliferative Disorders | 3 | 1988 | 19 | 0.110 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 19 | 0.110 |
Why?
|
| Antigens, CD1 | 3 | 2015 | 6 | 0.110 |
Why?
|
| Chemokine CCL4 | 3 | 2007 | 8 | 0.110 |
Why?
|
| Myeloid Cells | 1 | 2012 | 16 | 0.110 |
Why?
|
| Chemokine CCL3 | 3 | 2007 | 12 | 0.110 |
Why?
|
| Darunavir | 3 | 2019 | 3 | 0.110 |
Why?
|
| Brain Neoplasms | 3 | 1983 | 124 | 0.110 |
Why?
|
| Cholesterol | 1 | 2012 | 50 | 0.110 |
Why?
|
| Phytohemagglutinins | 5 | 2001 | 9 | 0.110 |
Why?
|
| Primates | 1 | 2012 | 17 | 0.110 |
Why?
|
| Frail Elderly | 2 | 2023 | 51 | 0.110 |
Why?
|
| Kenya | 3 | 2021 | 7 | 0.110 |
Why?
|
| beta 2-Microglobulin | 2 | 1992 | 3 | 0.110 |
Why?
|
| Genotype | 6 | 2016 | 405 | 0.110 |
Why?
|
| Health Services Research | 1 | 2012 | 41 | 0.110 |
Why?
|
| Oligopeptides | 1 | 2012 | 30 | 0.110 |
Why?
|
| Pyridines | 1 | 2012 | 42 | 0.110 |
Why?
|
| Disease Susceptibility | 5 | 2016 | 80 | 0.110 |
Why?
|
| Lysophosphatidylcholines | 2 | 2022 | 7 | 0.110 |
Why?
|
| Tetanus Toxoid | 4 | 2014 | 10 | 0.110 |
Why?
|
| Retrospective Studies | 7 | 2022 | 3273 | 0.100 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2009 | 18 | 0.100 |
Why?
|
| Complement Pathway, Classical | 4 | 1999 | 5 | 0.100 |
Why?
|
| DNA, Neoplasm | 2 | 1988 | 25 | 0.100 |
Why?
|
| Biomarkers, Tumor | 2 | 2014 | 175 | 0.100 |
Why?
|
| Hepatitis C Antibodies | 2 | 2008 | 7 | 0.100 |
Why?
|
| Glycomics | 2 | 2021 | 5 | 0.100 |
Why?
|
| Serum | 1 | 2011 | 9 | 0.100 |
Why?
|
| Alzheimer Disease | 2 | 2013 | 1942 | 0.100 |
Why?
|
| Neopterin | 4 | 2015 | 4 | 0.100 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 1 | 1991 | 1 | 0.100 |
Why?
|
| Prevalence | 4 | 2021 | 487 | 0.100 |
Why?
|
| Chlamydia Infections | 2 | 2008 | 8 | 0.100 |
Why?
|
| CTLA-4 Antigen | 2 | 2008 | 6 | 0.100 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2011 | 2 | 0.100 |
Why?
|
| Macaca mulatta | 5 | 2013 | 65 | 0.100 |
Why?
|
| Lopinavir | 2 | 2010 | 2 | 0.100 |
Why?
|
| DNA Primers | 3 | 2000 | 51 | 0.100 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2010 | 2 | 0.100 |
Why?
|
| Placenta | 2 | 2001 | 13 | 0.100 |
Why?
|
| Viral Core Proteins | 1 | 1990 | 4 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2000 | 13 | 0.100 |
Why?
|
| Caspase 8 | 1 | 2010 | 11 | 0.100 |
Why?
|
| Cell Survival | 4 | 2014 | 169 | 0.100 |
Why?
|
| Immunocompromised Host | 2 | 2021 | 45 | 0.100 |
Why?
|
| Adoptive Transfer | 2 | 2002 | 44 | 0.100 |
Why?
|
| Blood Specimen Collection | 2 | 2006 | 11 | 0.100 |
Why?
|
| Immunization | 3 | 2015 | 47 | 0.090 |
Why?
|
| Oxygen Consumption | 2 | 1989 | 49 | 0.090 |
Why?
|
| Cell Count | 2 | 2008 | 99 | 0.090 |
Why?
|
| Women's Health | 4 | 2017 | 246 | 0.090 |
Why?
|
| CD40 Antigens | 3 | 2015 | 9 | 0.090 |
Why?
|
| Monkey Diseases | 1 | 2010 | 1 | 0.090 |
Why?
|
| ADP-ribosyl Cyclase | 3 | 2000 | 5 | 0.090 |
Why?
|
| Cross-Over Studies | 2 | 2023 | 78 | 0.090 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2000 | 12 | 0.090 |
Why?
|
| Acute Disease | 2 | 2007 | 226 | 0.090 |
Why?
|
| Liver X Receptors | 1 | 2009 | 1 | 0.090 |
Why?
|
| Receptors, Interleukin-7 | 2 | 2006 | 3 | 0.090 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2009 | 3 | 0.090 |
Why?
|
| Cluster Analysis | 3 | 2017 | 52 | 0.090 |
Why?
|
| Bacterial Infections | 2 | 2021 | 69 | 0.090 |
Why?
|
| Cytoplasmic Granules | 3 | 1999 | 9 | 0.090 |
Why?
|
| Receptors, Immunologic | 2 | 2007 | 34 | 0.090 |
Why?
|
| fas Receptor | 2 | 2000 | 11 | 0.090 |
Why?
|
| Macaca | 3 | 2015 | 4 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2014 | 437 | 0.090 |
Why?
|
| SAIDS Vaccines | 1 | 2009 | 1 | 0.090 |
Why?
|
| Virus Inactivation | 1 | 2009 | 1 | 0.090 |
Why?
|
| Tunica Intima | 3 | 2015 | 26 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 340 | 0.090 |
Why?
|
| Mucus | 1 | 2008 | 8 | 0.090 |
Why?
|
| HIV Envelope Protein gp120 | 3 | 2006 | 19 | 0.090 |
Why?
|
| Chemokines, CC | 1 | 2008 | 8 | 0.090 |
Why?
|
| Epitopes | 5 | 2017 | 81 | 0.090 |
Why?
|
| Flaviviridae | 2 | 1998 | 2 | 0.080 |
Why?
|
| Brain | 1 | 2018 | 1689 | 0.080 |
Why?
|
| Serologic Tests | 2 | 2022 | 15 | 0.080 |
Why?
|
| Urine | 1 | 1988 | 9 | 0.080 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2008 | 2 | 0.080 |
Why?
|
| Hemophilia A | 3 | 1983 | 41 | 0.080 |
Why?
|
| Urogenital System | 1 | 2008 | 1 | 0.080 |
Why?
|
| Ganciclovir | 2 | 1998 | 26 | 0.080 |
Why?
|
| Chlamydia trachomatis | 1 | 2008 | 18 | 0.080 |
Why?
|
| HLA-B Antigens | 2 | 2007 | 10 | 0.080 |
Why?
|
| Emtricitabine | 2 | 2019 | 3 | 0.080 |
Why?
|
| Feedback, Physiological | 1 | 2008 | 15 | 0.080 |
Why?
|
| South Africa | 2 | 2018 | 17 | 0.080 |
Why?
|
| Cyclooxygenase 2 | 1 | 2008 | 30 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2008 | 6 | 0.080 |
Why?
|
| Candida | 3 | 2009 | 16 | 0.080 |
Why?
|
| Skin | 2 | 2006 | 117 | 0.080 |
Why?
|
| Ki-67 Antigen | 1 | 2007 | 13 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 145 | 0.080 |
Why?
|
| Secretory Leukocyte Peptidase Inhibitor | 1 | 2007 | 1 | 0.080 |
Why?
|
| Heterosexuality | 1 | 2007 | 3 | 0.080 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 3 | 2012 | 13 | 0.080 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 938 | 0.080 |
Why?
|
| Unsafe Sex | 1 | 2007 | 7 | 0.080 |
Why?
|
| Mutation | 4 | 2003 | 383 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 49 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2008 | 54 | 0.080 |
Why?
|
| Uterine Cervical Diseases | 1 | 2007 | 4 | 0.080 |
Why?
|
| Drug Hypersensitivity | 1 | 2007 | 17 | 0.080 |
Why?
|
| Chemokines, CXC | 1 | 2007 | 5 | 0.080 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 3 | 2006 | 5 | 0.080 |
Why?
|
| Neuropsychological Tests | 2 | 2022 | 1251 | 0.080 |
Why?
|
| Stavudine | 1 | 2007 | 1 | 0.080 |
Why?
|
| Receptors, Prostaglandin | 1 | 2007 | 2 | 0.080 |
Why?
|
| Interleukin-18 | 1 | 2007 | 11 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2008 | 123 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2007 | 25 | 0.080 |
Why?
|
| Interleukin-1 | 2 | 2005 | 78 | 0.080 |
Why?
|
| Neurodegenerative Diseases | 1 | 2008 | 117 | 0.080 |
Why?
|
| Diagnostic Services | 1 | 2006 | 1 | 0.080 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 328 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 1 | 1987 | 34 | 0.070 |
Why?
|
| AIDS Serodiagnosis | 1 | 2006 | 6 | 0.070 |
Why?
|
| Endothelial Cells | 2 | 2023 | 63 | 0.070 |
Why?
|
| Blood | 2 | 2019 | 25 | 0.070 |
Why?
|
| Enterobacteriaceae | 1 | 2006 | 30 | 0.070 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2006 | 2 | 0.070 |
Why?
|
| Immunoglobulin Allotypes | 1 | 1986 | 1 | 0.070 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 1986 | 4 | 0.070 |
Why?
|
| Major Histocompatibility Complex | 2 | 1983 | 13 | 0.070 |
Why?
|
| Sjogren's Syndrome | 1 | 1986 | 4 | 0.070 |
Why?
|
| Blood Preservation | 1 | 2006 | 4 | 0.070 |
Why?
|
| Centrifugation, Density Gradient | 1 | 2006 | 13 | 0.070 |
Why?
|
| Intermediate Filaments | 1 | 1986 | 17 | 0.070 |
Why?
|
| Reference Values | 5 | 2006 | 227 | 0.070 |
Why?
|
| Lectins, C-Type | 2 | 2022 | 106 | 0.070 |
Why?
|
| Research Design | 1 | 2008 | 212 | 0.070 |
Why?
|
| Langerhans Cells | 1 | 2006 | 2 | 0.070 |
Why?
|
| Cytoskeleton | 1 | 1986 | 51 | 0.070 |
Why?
|
| Phagocytosis | 2 | 2021 | 55 | 0.070 |
Why?
|
| Statistics, Nonparametric | 2 | 2003 | 138 | 0.070 |
Why?
|
| Placebos | 2 | 2016 | 77 | 0.070 |
Why?
|
| NFATC Transcription Factors | 1 | 2006 | 15 | 0.070 |
Why?
|
| Liver | 2 | 2019 | 173 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 432 | 0.070 |
Why?
|
| Lymphokines | 2 | 2001 | 9 | 0.070 |
Why?
|
| Protein Precursors | 2 | 2021 | 19 | 0.070 |
Why?
|
| Penis | 2 | 2006 | 67 | 0.070 |
Why?
|
| Rats, Inbred F344 | 3 | 1983 | 48 | 0.070 |
Why?
|
| Receptors, Complement | 3 | 1995 | 5 | 0.070 |
Why?
|
| Cell Lineage | 2 | 2015 | 29 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2016 | 82 | 0.070 |
Why?
|
| Isoantigens | 4 | 2000 | 5 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 1113 | 0.070 |
Why?
|
| Ficoll | 2 | 2006 | 2 | 0.070 |
Why?
|
| Gene Expression | 2 | 2023 | 226 | 0.070 |
Why?
|
| Reactive Oxygen Species | 2 | 2018 | 125 | 0.060 |
Why?
|
| Ribavirin | 2 | 2016 | 32 | 0.060 |
Why?
|
| Sevelamer | 2 | 2014 | 2 | 0.060 |
Why?
|
| Glycoproteins | 2 | 2015 | 58 | 0.060 |
Why?
|
| Glycosylation | 2 | 2020 | 24 | 0.060 |
Why?
|
| Lysosomes | 1 | 1984 | 24 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2004 | 23 | 0.060 |
Why?
|
| Papillomaviridae | 2 | 2007 | 29 | 0.060 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2003 | 22 | 0.060 |
Why?
|
| Genes, MDR | 1 | 2003 | 1 | 0.060 |
Why?
|
| Luteal Phase | 2 | 2000 | 6 | 0.060 |
Why?
|
| B7-2 Antigen | 3 | 2008 | 7 | 0.060 |
Why?
|
| Tobacco Smoking | 1 | 2023 | 4 | 0.060 |
Why?
|
| Chicago | 3 | 2017 | 865 | 0.060 |
Why?
|
| Human T-lymphotropic virus 1 | 2 | 1995 | 12 | 0.060 |
Why?
|
| Chest Pain | 1 | 2023 | 24 | 0.060 |
Why?
|
| Telomere | 2 | 2003 | 6 | 0.060 |
Why?
|
| Integrins | 1 | 2023 | 19 | 0.060 |
Why?
|
| DNA, Mitochondrial | 1 | 2003 | 9 | 0.060 |
Why?
|
| Hemoglobins | 1 | 2004 | 81 | 0.060 |
Why?
|
| NAD+ Nucleosidase | 2 | 2000 | 2 | 0.060 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 391 | 0.060 |
Why?
|
| Hepatitis A Vaccines | 3 | 2014 | 3 | 0.060 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2003 | 24 | 0.060 |
Why?
|
| Vaginal Smears | 1 | 2003 | 17 | 0.060 |
Why?
|
| Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2023 | 4 | 0.060 |
Why?
|
| Alcohol Drinking | 1 | 2024 | 78 | 0.060 |
Why?
|
| Transcription Factor AP-1 | 3 | 1999 | 16 | 0.060 |
Why?
|
| NAD | 1 | 2022 | 7 | 0.060 |
Why?
|
| Natural Killer T-Cells | 2 | 2016 | 5 | 0.060 |
Why?
|
| Nucleocapsid | 1 | 2022 | 3 | 0.060 |
Why?
|
| Coronary Vessels | 1 | 2023 | 46 | 0.060 |
Why?
|
| Bayes Theorem | 1 | 2023 | 39 | 0.060 |
Why?
|
| Liver Diseases | 2 | 2015 | 41 | 0.060 |
Why?
|
| Proteinuria | 1 | 2023 | 81 | 0.060 |
Why?
|
| Single-Cell Analysis | 1 | 2022 | 7 | 0.060 |
Why?
|
| Lymphocyte Culture Test, Mixed | 4 | 2007 | 8 | 0.060 |
Why?
|
| Syk Kinase | 1 | 2022 | 10 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 1 | 2022 | 42 | 0.060 |
Why?
|
| RNA | 1 | 2022 | 39 | 0.050 |
Why?
|
| Proteomics | 1 | 2023 | 91 | 0.050 |
Why?
|
| Feces | 2 | 2017 | 98 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 2 | 2000 | 96 | 0.050 |
Why?
|
| Puerto Rico | 2 | 2016 | 12 | 0.050 |
Why?
|
| Enhancer Elements, Genetic | 2 | 1999 | 11 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 4 | 1998 | 40 | 0.050 |
Why?
|
| Verbal Learning | 1 | 2022 | 42 | 0.050 |
Why?
|
| Genes, gag | 1 | 2002 | 3 | 0.050 |
Why?
|
| Mental Recall | 1 | 2022 | 74 | 0.050 |
Why?
|
| Longevity | 1 | 2022 | 32 | 0.050 |
Why?
|
| Complement C3 | 2 | 1993 | 7 | 0.050 |
Why?
|
| Survivors | 1 | 2022 | 57 | 0.050 |
Why?
|
| Citric Acid | 1 | 2021 | 2 | 0.050 |
Why?
|
| Haplorhini | 1 | 2021 | 12 | 0.050 |
Why?
|
| Haptoglobins | 1 | 2021 | 5 | 0.050 |
Why?
|
| Mitogens | 2 | 1996 | 7 | 0.050 |
Why?
|
| Rats, Inbred Strains | 1 | 1981 | 33 | 0.050 |
Why?
|
| Public Health | 1 | 2022 | 60 | 0.050 |
Why?
|
| Reference Standards | 2 | 2008 | 33 | 0.050 |
Why?
|
| Games, Experimental | 1 | 2021 | 9 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2022 | 88 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 306 | 0.050 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 2 | 1999 | 11 | 0.050 |
Why?
|
| Tight Junctions | 1 | 2021 | 28 | 0.050 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2021 | 9 | 0.050 |
Why?
|
| Blood Cell Count | 2 | 2008 | 15 | 0.050 |
Why?
|
| Urbanization | 1 | 2021 | 3 | 0.050 |
Why?
|
| Immunologic Techniques | 1 | 2001 | 3 | 0.050 |
Why?
|
| Dust | 1 | 2021 | 6 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 17 | 0.050 |
Why?
|
| Phosphatidylcholines | 1 | 2021 | 5 | 0.050 |
Why?
|
| Vital Capacity | 1 | 2021 | 9 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2021 | 12 | 0.050 |
Why?
|
| Receptors, Complement 3d | 4 | 1995 | 4 | 0.050 |
Why?
|
| Growth Inhibitors | 1 | 2001 | 14 | 0.050 |
Why?
|
| Lymph Nodes | 2 | 1999 | 70 | 0.050 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 33 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2021 | 25 | 0.050 |
Why?
|
| Geriatric Assessment | 1 | 2022 | 219 | 0.050 |
Why?
|
| Permeability | 1 | 2021 | 134 | 0.050 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2000 | 5 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2021 | 32 | 0.050 |
Why?
|
| Disease Management | 1 | 2022 | 114 | 0.050 |
Why?
|
| Memory Disorders | 1 | 2022 | 174 | 0.050 |
Why?
|
| Disease Reservoirs | 1 | 2000 | 10 | 0.050 |
Why?
|
| Drug Design | 1 | 2001 | 30 | 0.050 |
Why?
|
| Follicular Phase | 1 | 2000 | 3 | 0.050 |
Why?
|
| Lung Diseases | 1 | 2021 | 46 | 0.050 |
Why?
|
| Estradiol | 1 | 2000 | 58 | 0.050 |
Why?
|
| Indinavir | 1 | 2000 | 2 | 0.050 |
Why?
|
| L-Selectin | 1 | 2000 | 13 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2020 | 7 | 0.050 |
Why?
|
| Kinetics | 2 | 1999 | 225 | 0.050 |
Why?
|
| Memory | 1 | 2022 | 318 | 0.050 |
Why?
|
| Hemocyanins | 1 | 2000 | 1 | 0.050 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2000 | 1 | 0.050 |
Why?
|
| Mumps virus | 1 | 2000 | 1 | 0.050 |
Why?
|
| Glycolysis | 1 | 2020 | 20 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2020 | 35 | 0.050 |
Why?
|
| Leukapheresis | 1 | 2000 | 2 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2000 | 5 | 0.050 |
Why?
|
| HIV Fusion Inhibitors | 2 | 2013 | 3 | 0.050 |
Why?
|
| Antigens, CD34 | 1 | 2000 | 14 | 0.050 |
Why?
|
| Program Development | 1 | 2000 | 69 | 0.050 |
Why?
|
| Electrocardiography | 1 | 2021 | 209 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 3 | 1995 | 56 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2017 | 1184 | 0.050 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 215 | 0.050 |
Why?
|
| Gene Products, env | 2 | 1999 | 13 | 0.050 |
Why?
|
| Drug Synergism | 2 | 1998 | 63 | 0.050 |
Why?
|
| Glutathione | 1 | 2019 | 30 | 0.040 |
Why?
|
| Boston | 1 | 2019 | 27 | 0.040 |
Why?
|
| Glutamine | 1 | 2019 | 9 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 1999 | 17 | 0.040 |
Why?
|
| Virulence | 1 | 1999 | 15 | 0.040 |
Why?
|
| Glutamic Acid | 1 | 2019 | 32 | 0.040 |
Why?
|
| Neuropsychology | 1 | 2019 | 11 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2000 | 277 | 0.040 |
Why?
|
| Bacterial Vaccines | 1 | 1999 | 4 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 1 | 1999 | 6 | 0.040 |
Why?
|
| Genes | 3 | 1988 | 8 | 0.040 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2019 | 49 | 0.040 |
Why?
|
| Pneumococcal Infections | 1 | 1999 | 9 | 0.040 |
Why?
|
| Th1 Cells | 1 | 1999 | 29 | 0.040 |
Why?
|
| Occupational Diseases | 1 | 1999 | 21 | 0.040 |
Why?
|
| Leukemia | 4 | 1987 | 10 | 0.040 |
Why?
|
| Obesity | 1 | 2022 | 291 | 0.040 |
Why?
|
| Veterans | 1 | 2020 | 63 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1999 | 29 | 0.040 |
Why?
|
| Educational Status | 1 | 2020 | 295 | 0.040 |
Why?
|
| Rats | 5 | 1986 | 854 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2019 | 124 | 0.040 |
Why?
|
| Mice, Knockout, ApoE | 1 | 2018 | 1 | 0.040 |
Why?
|
| Freund's Adjuvant | 1 | 2018 | 1 | 0.040 |
Why?
|
| Epitope Mapping | 1 | 2018 | 2 | 0.040 |
Why?
|
| B7-1 Antigen | 2 | 2008 | 12 | 0.040 |
Why?
|
| Aortic Diseases | 1 | 2018 | 6 | 0.040 |
Why?
|
| Vaginitis | 1 | 1998 | 4 | 0.040 |
Why?
|
| Pneumonia, Pneumocystis | 2 | 1993 | 32 | 0.040 |
Why?
|
| Tumor Virus Infections | 1 | 1998 | 15 | 0.040 |
Why?
|
| Receptors, Chemokine | 1 | 1998 | 11 | 0.040 |
Why?
|
| Aorta | 1 | 2018 | 26 | 0.040 |
Why?
|
| Age Distribution | 2 | 2008 | 94 | 0.040 |
Why?
|
| Bone Development | 1 | 2018 | 32 | 0.040 |
Why?
|
| Hepatitis Antibodies | 1 | 1998 | 1 | 0.040 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1998 | 7 | 0.040 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2018 | 2 | 0.040 |
Why?
|
| Jurkat Cells | 2 | 2013 | 10 | 0.040 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2018 | 80 | 0.040 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2018 | 8 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 2 | 2015 | 43 | 0.040 |
Why?
|
| Genitalia | 1 | 2017 | 2 | 0.040 |
Why?
|
| Heating | 1 | 1997 | 3 | 0.040 |
Why?
|
| Myxovirus Resistance Proteins | 1 | 2017 | 3 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2018 | 56 | 0.040 |
Why?
|
| Ubiquitins | 1 | 2017 | 8 | 0.040 |
Why?
|
| Antibody Affinity | 1 | 2017 | 3 | 0.040 |
Why?
|
| Colitis | 1 | 2017 | 37 | 0.040 |
Why?
|
| Endopeptidases | 1 | 1997 | 29 | 0.040 |
Why?
|
| Maternal-Fetal Exchange | 1 | 1997 | 10 | 0.040 |
Why?
|
| STAT5 Transcription Factor | 1 | 2017 | 1 | 0.040 |
Why?
|
| Galectin 3 | 1 | 2017 | 3 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 3 | 1991 | 263 | 0.040 |
Why?
|
| Autoimmune Diseases | 2 | 2016 | 61 | 0.040 |
Why?
|
| Pathology, Clinical | 2 | 1987 | 3 | 0.040 |
Why?
|
| Sleep | 1 | 2020 | 313 | 0.040 |
Why?
|
| Clone Cells | 3 | 2003 | 20 | 0.040 |
Why?
|
| Decision Trees | 2 | 2006 | 16 | 0.040 |
Why?
|
| Interferons | 1 | 2016 | 13 | 0.040 |
Why?
|
| Positive Regulatory Domain I-Binding Factor 1 | 1 | 2016 | 2 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2016 | 2 | 0.040 |
Why?
|
| Germinal Center | 1 | 2016 | 2 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2016 | 3 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2016 | 6 | 0.040 |
Why?
|
| Indomethacin | 1 | 1996 | 9 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 770 | 0.040 |
Why?
|
| Dinoprostone | 1 | 1996 | 30 | 0.040 |
Why?
|
| Antigen-Antibody Reactions | 2 | 1988 | 9 | 0.040 |
Why?
|
| Reproductive Tract Infections | 1 | 2016 | 1 | 0.040 |
Why?
|
| Cost of Illness | 2 | 2006 | 54 | 0.040 |
Why?
|
| Sulfoxides | 1 | 2016 | 6 | 0.040 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1996 | 6 | 0.040 |
Why?
|
| Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 1 | 2016 | 1 | 0.040 |
Why?
|
| Neurons | 1 | 2019 | 374 | 0.040 |
Why?
|
| Electroporation | 1 | 2016 | 2 | 0.040 |
Why?
|
| Sulfasalazine | 1 | 2016 | 3 | 0.040 |
Why?
|
| Respiratory Mucosa | 1 | 2016 | 4 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2016 | 36 | 0.040 |
Why?
|
| Viruses | 1 | 2016 | 7 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1996 | 29 | 0.040 |
Why?
|
| Biofilms | 1 | 2016 | 15 | 0.030 |
Why?
|
| Probiotics | 1 | 2016 | 20 | 0.030 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 1995 | 1 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 1996 | 145 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2022 | 957 | 0.030 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1996 | 24 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 248 | 0.030 |
Why?
|
| Accidents, Occupational | 1 | 1995 | 3 | 0.030 |
Why?
|
| Medical Waste | 1 | 1995 | 2 | 0.030 |
Why?
|
| Injections, Subcutaneous | 2 | 2007 | 32 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 65 | 0.030 |
Why?
|
| Hypersensitivity | 1 | 2016 | 48 | 0.030 |
Why?
|
| Cervix Mucus | 1 | 2015 | 4 | 0.030 |
Why?
|
| Retroviridae Infections | 1 | 1995 | 1 | 0.030 |
Why?
|
| Spumavirus | 1 | 1995 | 1 | 0.030 |
Why?
|
| Prevotella | 1 | 2015 | 2 | 0.030 |
Why?
|
| Ruminococcus | 1 | 2015 | 2 | 0.030 |
Why?
|
| Graves Disease | 1 | 1995 | 3 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2016 | 156 | 0.030 |
Why?
|
| Complement C4b | 1 | 1995 | 2 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2016 | 85 | 0.030 |
Why?
|
| MEDLINE | 1 | 2015 | 5 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 47 | 0.030 |
Why?
|
| Color | 1 | 1995 | 7 | 0.030 |
Why?
|
| Receptors, Complement 3b | 1 | 1995 | 15 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2015 | 28 | 0.030 |
Why?
|
| Pelvic Bones | 1 | 2015 | 20 | 0.030 |
Why?
|
| Illinois | 1 | 2016 | 241 | 0.030 |
Why?
|
| Quality of Life | 1 | 2020 | 662 | 0.030 |
Why?
|
| Aspirin | 1 | 2016 | 83 | 0.030 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2016 | 88 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 1989 | 35 | 0.030 |
Why?
|
| Circumcision, Male | 2 | 2006 | 6 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 298 | 0.030 |
Why?
|
| Histocytochemistry | 2 | 1984 | 26 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2014 | 9 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 42 | 0.030 |
Why?
|
| World Health Organization | 1 | 2014 | 18 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2014 | 37 | 0.030 |
Why?
|
| Calibration | 2 | 1995 | 22 | 0.030 |
Why?
|
| Containment of Biohazards | 1 | 1994 | 1 | 0.030 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2014 | 19 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 10 | 0.030 |
Why?
|
| Hemolysis | 1 | 1994 | 8 | 0.030 |
Why?
|
| Blood Cells | 1 | 1994 | 6 | 0.030 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 8 | 0.030 |
Why?
|
| Cytidine Deaminase | 1 | 2013 | 1 | 0.030 |
Why?
|
| Digestive System | 1 | 2013 | 16 | 0.030 |
Why?
|
| Eye | 1 | 2013 | 10 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 2015 | 115 | 0.030 |
Why?
|
| Pore Forming Cytotoxic Proteins | 2 | 2006 | 3 | 0.030 |
Why?
|
| Perforin | 2 | 2006 | 4 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2014 | 97 | 0.030 |
Why?
|
| Synovial Fluid | 2 | 1991 | 123 | 0.030 |
Why?
|
| Alleles | 2 | 2004 | 224 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 441 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2013 | 55 | 0.030 |
Why?
|
| Cathelicidins | 1 | 2013 | 1 | 0.030 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2013 | 2 | 0.030 |
Why?
|
| beta-Defensins | 1 | 2013 | 2 | 0.030 |
Why?
|
| Pathology | 1 | 1993 | 4 | 0.030 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 1993 | 4 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1993 | 11 | 0.030 |
Why?
|
| Fixatives | 1 | 1993 | 7 | 0.030 |
Why?
|
| Demography | 1 | 2013 | 77 | 0.030 |
Why?
|
| Observer Variation | 1 | 1993 | 118 | 0.030 |
Why?
|
| Lymphoma | 3 | 1987 | 44 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2013 | 95 | 0.030 |
Why?
|
| Scattering, Radiation | 1 | 1993 | 39 | 0.030 |
Why?
|
| Crosses, Genetic | 2 | 1983 | 13 | 0.030 |
Why?
|
| Postmortem Changes | 1 | 1992 | 34 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2007 | 219 | 0.030 |
Why?
|
| Ascitic Fluid | 2 | 1983 | 10 | 0.030 |
Why?
|
| Cell Membrane Permeability | 1 | 1993 | 56 | 0.030 |
Why?
|
| Fibrinogen | 1 | 2012 | 19 | 0.030 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2012 | 1 | 0.030 |
Why?
|
| Polypharmacy | 1 | 2012 | 10 | 0.030 |
Why?
|
| Cercocebus | 1 | 2012 | 2 | 0.030 |
Why?
|
| Antithrombins | 1 | 2012 | 3 | 0.030 |
Why?
|
| Thrombin | 1 | 2012 | 12 | 0.030 |
Why?
|
| Atazanavir Sulfate | 1 | 2012 | 1 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2012 | 47 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 53 | 0.030 |
Why?
|
| Neurofibrillary Tangles | 1 | 2013 | 181 | 0.030 |
Why?
|
| Cell Culture Techniques | 2 | 2003 | 44 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2012 | 59 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2012 | 55 | 0.030 |
Why?
|
| Life Style | 1 | 2013 | 211 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 1991 | 7 | 0.030 |
Why?
|
| Retroviridae | 2 | 1999 | 6 | 0.030 |
Why?
|
| Hot Temperature | 2 | 2008 | 23 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2011 | 22 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2012 | 60 | 0.030 |
Why?
|
| Synovitis | 1 | 1991 | 22 | 0.030 |
Why?
|
| Complement C1q | 1 | 1991 | 3 | 0.030 |
Why?
|
| Fetal Blood | 2 | 2003 | 16 | 0.030 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2011 | 7 | 0.030 |
Why?
|
| Societies, Medical | 1 | 1993 | 190 | 0.030 |
Why?
|
| AIDS-Related Complex | 1 | 1991 | 3 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 1988 | 6 | 0.030 |
Why?
|
| Amyloid beta-Peptides | 1 | 2013 | 294 | 0.030 |
Why?
|
| Algorithms | 1 | 2014 | 400 | 0.030 |
Why?
|
| Fetal Proteins | 1 | 2011 | 2 | 0.020 |
Why?
|
| T-Box Domain Proteins | 1 | 2011 | 6 | 0.020 |
Why?
|
| Models, Immunological | 1 | 2011 | 9 | 0.020 |
Why?
|
| Herpesvirus 6, Human | 1 | 1990 | 4 | 0.020 |
Why?
|
| Thrombocytopenia | 2 | 1988 | 30 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 2 | 1998 | 85 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2010 | 38 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2011 | 65 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2011 | 132 | 0.020 |
Why?
|
| Filgrastim | 2 | 2000 | 5 | 0.020 |
Why?
|
| Lymphocytes, Null | 1 | 1989 | 1 | 0.020 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2009 | 6 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 1990 | 73 | 0.020 |
Why?
|
| Fluoresceins | 1 | 1989 | 8 | 0.020 |
Why?
|
| Blood Bactericidal Activity | 1 | 1989 | 5 | 0.020 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 1989 | 5 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2011 | 145 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 1989 | 118 | 0.020 |
Why?
|
| Immunoglobulin M | 2 | 1986 | 19 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2009 | 109 | 0.020 |
Why?
|
| RNA, Bacterial | 1 | 2009 | 3 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2009 | 16 | 0.020 |
Why?
|
| 2,2'-Dipyridyl | 1 | 2009 | 1 | 0.020 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2009 | 13 | 0.020 |
Why?
|
| Mycobacterium avium Complex | 1 | 2009 | 2 | 0.020 |
Why?
|
| Disinfectants | 1 | 2009 | 8 | 0.020 |
Why?
|
| Disulfides | 1 | 2009 | 12 | 0.020 |
Why?
|
| Drug Stability | 1 | 2008 | 9 | 0.020 |
Why?
|
| Immunoglobulin Switch Region | 1 | 1988 | 1 | 0.020 |
Why?
|
| Retroviridae Proteins | 1 | 1988 | 2 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2008 | 50 | 0.020 |
Why?
|
| Species Specificity | 2 | 1991 | 70 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2008 | 40 | 0.020 |
Why?
|
| New South Wales | 1 | 2008 | 4 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2008 | 9 | 0.020 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2008 | 9 | 0.020 |
Why?
|
| Cognition | 1 | 2017 | 1277 | 0.020 |
Why?
|
| Carmustine | 2 | 1979 | 5 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2001 | 193 | 0.020 |
Why?
|
| Lymphocytosis | 1 | 1988 | 1 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 138 | 0.020 |
Why?
|
| North America | 1 | 2008 | 38 | 0.020 |
Why?
|
| Bias | 1 | 2008 | 33 | 0.020 |
Why?
|
| Chemokine CXCL1 | 1 | 2007 | 3 | 0.020 |
Why?
|
| Immunoglobulin Isotypes | 1 | 1987 | 8 | 0.020 |
Why?
|
| Immunoglobulin Light Chains | 1 | 1987 | 9 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 31 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2007 | 34 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2007 | 30 | 0.020 |
Why?
|
| Culture Media | 1 | 2007 | 38 | 0.020 |
Why?
|
| Corynebacterium | 1 | 2007 | 5 | 0.020 |
Why?
|
| Leukemia, Lymphoid | 1 | 1987 | 2 | 0.020 |
Why?
|
| Interleukin-23 | 1 | 2007 | 12 | 0.020 |
Why?
|
| Leukemia, Myeloid | 1 | 1987 | 5 | 0.020 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2007 | 8 | 0.020 |
Why?
|
| Endosomes | 1 | 2007 | 8 | 0.020 |
Why?
|
| Interleukin-1alpha | 1 | 2007 | 4 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2007 | 35 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2007 | 28 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2007 | 19 | 0.020 |
Why?
|
| Anemia, Aplastic | 1 | 1987 | 2 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2007 | 29 | 0.020 |
Why?
|
| Karyotyping | 1 | 1987 | 13 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 1989 | 125 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2007 | 116 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2007 | 76 | 0.020 |
Why?
|
| Cercocebus atys | 1 | 2006 | 1 | 0.020 |
Why?
|
| Syphilis | 1 | 2006 | 4 | 0.020 |
Why?
|
| Blood Donors | 2 | 1998 | 6 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1986 | 13 | 0.020 |
Why?
|
| Bacteriological Techniques | 1 | 2006 | 20 | 0.020 |
Why?
|
| Gonorrhea | 1 | 2006 | 8 | 0.020 |
Why?
|
| Receptors, Interleukin-15 | 1 | 2006 | 3 | 0.020 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2006 | 8 | 0.020 |
Why?
|
| Logistic Models | 1 | 2008 | 407 | 0.020 |
Why?
|
| Paraproteins | 1 | 1986 | 2 | 0.020 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 1986 | 5 | 0.020 |
Why?
|
| CpG Islands | 1 | 2006 | 34 | 0.020 |
Why?
|
| Viral Matrix Proteins | 1 | 2006 | 4 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1987 | 73 | 0.020 |
Why?
|
| Histological Techniques | 1 | 1986 | 6 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2006 | 26 | 0.020 |
Why?
|
| Swine | 1 | 1986 | 80 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 78 | 0.020 |
Why?
|
| Dementia | 1 | 2011 | 521 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2006 | 91 | 0.020 |
Why?
|
| Antigens, Ly | 1 | 1985 | 2 | 0.020 |
Why?
|
| Autoantibodies | 1 | 1986 | 100 | 0.020 |
Why?
|
| Organ Size | 1 | 2005 | 107 | 0.020 |
Why?
|
| Receptors, KIR | 1 | 2004 | 2 | 0.020 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2004 | 2 | 0.020 |
Why?
|
| Naphthol AS D Esterase | 1 | 1984 | 1 | 0.020 |
Why?
|
| Acid Phosphatase | 1 | 1984 | 4 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2004 | 75 | 0.020 |
Why?
|
| Immunization Schedule | 1 | 2004 | 1 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 2004 | 3 | 0.020 |
Why?
|
| Immunization, Secondary | 1 | 2004 | 7 | 0.020 |
Why?
|
| Thailand | 1 | 2004 | 11 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2004 | 81 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2004 | 36 | 0.020 |
Why?
|
| Rats, Inbred BN | 1 | 1983 | 4 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 1983 | 11 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2004 | 48 | 0.010 |
Why?
|
| RNA, Ribosomal, 18S | 1 | 2003 | 2 | 0.010 |
Why?
|
| Hepatitis B virus | 1 | 1983 | 7 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2003 | 58 | 0.010 |
Why?
|
| Mycobacterium Infections | 1 | 1983 | 4 | 0.010 |
Why?
|
| Graft Rejection | 1 | 1983 | 76 | 0.010 |
Why?
|
| Antigens, CD1d | 1 | 2003 | 3 | 0.010 |
Why?
|
| Hepatitis B Vaccines | 1 | 2003 | 7 | 0.010 |
Why?
|
| Factor VIII | 1 | 1983 | 26 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2003 | 105 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2002 | 26 | 0.010 |
Why?
|
| Etanercept | 1 | 2002 | 23 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2002 | 67 | 0.010 |
Why?
|
| Blood Component Removal | 1 | 2002 | 1 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2003 | 285 | 0.010 |
Why?
|
| Biological Factors | 1 | 2001 | 9 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2001 | 37 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1981 | 23 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2002 | 195 | 0.010 |
Why?
|
| Receptors, OSM-LIF | 1 | 2001 | 1 | 0.010 |
Why?
|
| Leukemia Inhibitory Factor Receptor alpha Subunit | 1 | 2001 | 1 | 0.010 |
Why?
|
| Contactins | 1 | 2001 | 1 | 0.010 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 2001 | 3 | 0.010 |
Why?
|
| Receptors, Cytokine | 1 | 2001 | 4 | 0.010 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2001 | 2 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2002 | 227 | 0.010 |
Why?
|
| HIV Envelope Protein gp160 | 1 | 2000 | 2 | 0.010 |
Why?
|
| Abortion, Spontaneous | 1 | 2000 | 9 | 0.010 |
Why?
|
| Pokeweed Mitogens | 1 | 2000 | 1 | 0.010 |
Why?
|
| Streptokinase | 1 | 2000 | 2 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2000 | 55 | 0.010 |
Why?
|
| Transportation | 1 | 2000 | 3 | 0.010 |
Why?
|
| Structure-Activity Relationship | 2 | 1993 | 44 | 0.010 |
Why?
|
| Injections, Intradermal | 1 | 2000 | 2 | 0.010 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2000 | 9 | 0.010 |
Why?
|
| HIV Protease | 1 | 2000 | 9 | 0.010 |
Why?
|
| Tomography | 1 | 2000 | 11 | 0.010 |
Why?
|
| Granzymes | 1 | 1999 | 7 | 0.010 |
Why?
|
| Mycoplasma | 1 | 1999 | 4 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1999 | 5 | 0.010 |
Why?
|
| Chemical Fractionation | 1 | 1999 | 7 | 0.010 |
Why?
|
| Premedication | 1 | 1999 | 4 | 0.010 |
Why?
|
| Pneumococcal Vaccines | 1 | 1999 | 5 | 0.010 |
Why?
|
| Ohio | 1 | 1998 | 9 | 0.010 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 1998 | 10 | 0.010 |
Why?
|
| Body Temperature | 1 | 1979 | 58 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1998 | 24 | 0.010 |
Why?
|
| Databases as Topic | 1 | 1998 | 19 | 0.010 |
Why?
|
| Virus Integration | 1 | 1998 | 9 | 0.010 |
Why?
|
| Protein Binding | 2 | 1991 | 127 | 0.010 |
Why?
|
| Immediate-Early Proteins | 1 | 1998 | 6 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 1998 | 9 | 0.010 |
Why?
|
| Fetus | 1 | 1998 | 56 | 0.010 |
Why?
|
| Immunoglobulin Constant Regions | 2 | 1988 | 2 | 0.010 |
Why?
|
| Translocation, Genetic | 2 | 1988 | 8 | 0.010 |
Why?
|
| Recombination, Genetic | 2 | 1988 | 13 | 0.010 |
Why?
|
| Chromosome Deletion | 2 | 1988 | 28 | 0.010 |
Why?
|
| Patient Selection | 1 | 2000 | 232 | 0.010 |
Why?
|
| Immunoglobulin A, Secretory | 1 | 1997 | 6 | 0.010 |
Why?
|
| Molecular Weight | 2 | 1988 | 45 | 0.010 |
Why?
|
| Infection Control | 1 | 1999 | 169 | 0.010 |
Why?
|
| Propionibacterium acnes | 1 | 1977 | 8 | 0.010 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1997 | 1 | 0.010 |
Why?
|
| Luminescent Measurements | 2 | 1986 | 20 | 0.010 |
Why?
|
| Lymphotoxin-alpha | 1 | 1996 | 6 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1996 | 11 | 0.010 |
Why?
|
| Drug Eruptions | 1 | 1996 | 10 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1996 | 30 | 0.010 |
Why?
|
| HTLV-I Antibodies | 1 | 1995 | 1 | 0.010 |
Why?
|
| Cell-Free System | 1 | 1995 | 3 | 0.010 |
Why?
|
| HTLV-I Infections | 1 | 1995 | 5 | 0.010 |
Why?
|
| Antibodies, Blocking | 1 | 1995 | 7 | 0.010 |
Why?
|
| Zalcitabine | 1 | 1995 | 2 | 0.010 |
Why?
|
| Needlestick Injuries | 1 | 1995 | 2 | 0.010 |
Why?
|
| Antigens, CD19 | 1 | 1995 | 1 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1995 | 13 | 0.010 |
Why?
|
| Complement C4 | 1 | 1995 | 4 | 0.010 |
Why?
|
| Fluorescence | 1 | 1995 | 12 | 0.010 |
Why?
|
| Tissue Donors | 1 | 1995 | 74 | 0.010 |
Why?
|
| Blood-Borne Pathogens | 1 | 1994 | 3 | 0.010 |
Why?
|
| Hospitals, University | 1 | 1994 | 39 | 0.010 |
Why?
|
| Research | 1 | 1992 | 54 | 0.010 |
Why?
|
| Histocompatibility Antigens | 1 | 1992 | 3 | 0.010 |
Why?
|
| Integrin beta1 | 1 | 1992 | 9 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1991 | 63 | 0.010 |
Why?
|
| Lymphocyte Cooperation | 1 | 1991 | 2 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1991 | 17 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1992 | 389 | 0.010 |
Why?
|
| Lysogeny | 1 | 1990 | 1 | 0.010 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1990 | 1 | 0.010 |
Why?
|
| Viral Interference | 1 | 1990 | 1 | 0.010 |
Why?
|
| Rabbits | 1 | 1991 | 280 | 0.010 |
Why?
|
| Mental Disorders | 1 | 1992 | 140 | 0.010 |
Why?
|
| Mycoplasma Infections | 1 | 1990 | 3 | 0.010 |
Why?
|
| Deltaretrovirus Infections | 1 | 1990 | 2 | 0.010 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 1988 | 1 | 0.010 |
Why?
|
| Leukemia, B-Cell | 1 | 1988 | 1 | 0.010 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1988 | 3 | 0.010 |
Why?
|
| Platelet Count | 1 | 1988 | 20 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 1988 | 20 | 0.010 |
Why?
|
| Protein Conformation | 1 | 1988 | 69 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 1987 | 3 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1988 | 364 | 0.000 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1987 | 9 | 0.000 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1987 | 5 | 0.000 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1987 | 10 | 0.000 |
Why?
|
| HLA-DQ Antigens | 1 | 1987 | 7 | 0.000 |
Why?
|
| Zymosan | 1 | 1986 | 6 | 0.000 |
Why?
|
| Chromium Radioisotopes | 1 | 1986 | 2 | 0.000 |
Why?
|
| Paraffin | 1 | 1986 | 2 | 0.000 |
Why?
|
| Diploidy | 1 | 1986 | 4 | 0.000 |
Why?
|
| Cell Membrane | 1 | 1985 | 105 | 0.000 |
Why?
|
| Mycobacterium avium | 1 | 1983 | 1 | 0.000 |
Why?
|
| Herpesvirus 3, Human | 1 | 1983 | 5 | 0.000 |
Why?
|
| Simplexvirus | 1 | 1983 | 9 | 0.000 |
Why?
|
| Injections, Intraperitoneal | 1 | 1979 | 13 | 0.000 |
Why?
|
| Neoplasms, Experimental | 1 | 1977 | 10 | 0.000 |
Why?
|